Study Evaluating TCH346 and Placebo Administered Once Daily in Patients With Amyotrophic Lateral Sclerosis (ALS) - Contacts and Locations

Study Evaluating TCH346 and Placebo Administered Once Daily in Patients With Amyotrophic Lateral Sclerosis (ALS)

This study has been completed.

Study NCT00072709. Last updated on November 29, 2007. Information provided by Novartis

Please refer to this study by its ClinicalTrials.gov identifier: NCT00072709

Locations


United States, New Jersey
	Novartis USA
	East Hanover, New Jersey, United States, 07936

Belgium
	Novartis Belgium
	Vilvoorde, Belgium

Canada, Quebec
	Novartis CANADA
	Dorval, Quebec, Canada

France
	Novartis France
	Rueil-Malmaison, France

Germany
	Novartis Germany
	Nuernberg, Germany

Italy
	Novartis Italy
	Saronno, Italy

Netherlands
	Novartis Netherlands
	Arnhem, Netherlands

Switzerland
	Novartis Switzerland
	Bern, Switzerland

United Kingdom
	Novartis UK
	Frimley, United Kingdom

Sponsors and Collaborators

Novartis